|
1
|
Schröder FH: Prostate cancer around the
world. An overview. Urol Oncol. 28:663–667. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Malvezzi M, Arfé A, Bertuccio P, Levi F,
La Vecchia C and Negri E: European cancer mortality predictions for
the year 2011. Ann Oncol. 22:947–956. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pienta KJ and Bradley D: Mechanisms
underlying the development of androgen-independent prostate cancer.
Clin Cancer Res. 12:1665–1671. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hirano D, Nagane Y, Satoh K, Mochida J,
Sugimoto S, Ichinose T, Takahashi S, Maebayashi T and Saitoh T:
Neoadjuvant LHRH analog plus estramustine phosphate combined with
three-dimensional conformal radiotherapy for intermediate- to
high-risk prostate cancer: A randomized study. Int Urol Nephrol.
42:81–88. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Labrie F: Keyrole of endocrinology in the
victory against prostate cancer. Bull Cancer. 93:949–958. 2006.(In
French). PubMed/NCBI
|
|
6
|
Junco JA, Peschke P, Zuna I, Ehemann V,
Fuentes F, Bover E, Pimentel E, Basulto R, Reyes O, Calzada L, et
al: Immunotherapy of prostate cancer in a murine model using a
novel GnRH based vaccine candidate. Vaccine. 25:8460–8468. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Miyake H, Nelson C, Rennie PS and Gleave
ME: Testosterone-repressed prostate message-2 is an antiapoptotic
gene involved in progression to androgen independence in prostate
cancer. Cancer Res. 60:170–176. 2000.PubMed/NCBI
|
|
8
|
So AI, Bowden M and Gleave M: Effect of
time of castration and tumour volume on time to
androgen-independent recurrence in Shionogi tumours. BJU Int.
93:845–850. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hahn S, Nesslinger NJ, Drapala RJ, Bowden
M, Rennie PS, Pai HH, Ludgate C and Nelson BH: Castration induces
autoantibody and T cell responses that correlate with inferior
outcomes in an androgen-dependent murine tumor model. Int J Cancer.
125:2871–2878. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Talwar GP, Raina K, Gupta JC, Ray R,
Wadhwa S and Ali MM: A recombinant
luteinising-hormone-releasing-hormone immunogen bioeffective in
causing prostatic atrophy. Vaccine. 22:3713–3721. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Talwar GP, Vyas HK, Purswani S and Gupta
JC: Gonadotropin-releasing hormone/human chorionic gonadotropin
beta based recombinant antibodies and vaccines. J Reprod Immunol.
83:158–163. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Aguilar FF, Barranco JJ, Fuentes EB,
Aguilera LC, Sáez YL, Santana MD, Vázquez EP, Baker RB, Acosta OR,
Pérez HG and Nieto GG: Very small size proteoliposomes (VSSP) and
Montanide combination enhance the humoral immuno response in a GnRH
based vaccine directed to prostate cancer. Vaccine. 30:6595–6599.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ferro VA and Stimson WH: Investigation
into suitable carrier molecules for use in an anti-gonadotrophin
releasing hormone vaccine. Vaccine. 16:1095–1102. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ko EC, Wang X and Ferrone S: Immunotherapy
of malignant diseases. Challenges and strategies. Int Arch Allergy
Immunol. 132:294–309. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lage A, Perez R and Fernandez LE:
Therapeutic cancer vaccines: At midway between immunology and
pharmacology. Curr Cancer Drug Targets. 5:611–627. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Clements CJ and Griffiths E: The global
impact of vaccines containing aluminium adjuvants. Vaccine.
20(Suppl 3): S24–S33. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lell B, Agnandji S, von Glasenapp I,
Haertle S, Oyakhiromen S, Issifou S, Vekemans J, Leach A, Lievens
M, Dubois MC, et al: A randomized trial assessing the safety and
immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine
candidates in children in Gabon. PLoS One. 4:e76112009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Giannini SL, Hanon E, Moris P, Van
Mechelen M, Morel S, Dessy F, Fourneau MA, Colau B, Suzich J,
Losonksy G, et al: Enhanced humoral and memory B cellular immunity
using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium
salt combination (AS04) compared to aluminium salt only. Vaccine.
24:5937–5949. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Didierlaurent AM, Morel S, Lockman L,
Giannini SL, Bisteau M, Carlsen H, Kielland A, Vosters O,
Vanderheyde N, Schiavetti F, et al: AS04, an aluminum salt- and
TLR4 agonist-based adjuvant system, induces a transient localized
innate immune response leading to enhanced adaptive immunity. J
Immunol. 183:6186–6197. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schwarz TF: Clinical update of the
AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine,
Cervarix. Adv Ther. 26:983–998. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rennie PS, Bruchovsky N, Buttyan R, Benson
M and Cheng H: Gene expression during the early phases of
regression of the androgen-dependent Shionogi mouse mammary
carcinoma. Cancer Res. 48:6309–6312. 1988.PubMed/NCBI
|
|
22
|
Nesslinger NJ, Sahota RA, Stone B, Johnson
K, Chima N, King C, Rasmussen D, Bishop D, Rennie PS, Gleave M, et
al: Standard treatments induce antigen-specific immune responses in
prostate cancer. Clin Cancer Res. 13:1493–1502. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nesslinger NJ, Ng A, Tsang KY, Ferrara T,
Schlom J, Gulley JL and Nelson BH: A viral vaccine encoding
prostate-specific antigen induces antigen spreading to a common set
of self-proteins in prostate cancer patients. Clin Cancer Res.
16:4046–4056. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Carr A, Mazorra Z, Alonso DF, Mesa C,
Valiente O, Gomez DE, Perez R and Fernandez LE: A purified GM3
ganglioside conjugated vaccine induces specific, adjuvant-dependent
and non-transient antitumour activity against B16 mouse melanoma in
vitro and in vivo. Melanoma Res. 11:219–227. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Matzinger P: Tolerance, danger, and the
extended family. Annu Rev Immunol. 12:991–1045. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ambrosino DM, Bolon D, Collard H, Van
Etten R, Kanchana MV and Finberg RW: Effect of Haemophilus
influenzae polysaccharide outer membrane protein complex
conjugate vaccine on macrophages. J Immunol. 149:3978–3983.
1992.PubMed/NCBI
|
|
27
|
Udono H and Srivastava PK: Heat shock
protein 70-associated peptides elicit specific cancer immunity. J
Exp Med. 178:1391–1396. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nestle FO, Alijagic S, Gilliet M, Sun Y,
Grabbe S, Dummer R, Burg G and Schadendorf D: Vaccination of
melanoma patients with peptide- or tumor lysate-pulsed dendritic
cells. Nat Med. 4:328–332. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Andersen BM: Endotoxin release from
Neisseria meningitidis. Relationship between key bacterial
characteristics and meningococcal disease. Scand J Infect Dis
Suppl. 64(S64): 1–43. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zollinger WD: New and improved vaccines
against meningococal disease. New Generation Vaccines. Woodrow GC
and Levine MM: Marcel Dekker, Inc. (New York, NY). 325–348.
1990.
|
